Search research articles
Contact Us
Filters
Showing results (31-40 of 1,339) with videos related to
Page
of 134
Sort By:
The Journal of the Tennessee Dental Association
|
April 1, 1982
Touch your patient with love
P A Burger
Blood
|
January 9, 2016
Obinutuzumab: the more the merrier?
Jan A Burger
Blood
|
April 12, 2012
BRAF mutation: supporting diversity in HCL
Jan A Burger
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2011
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer
R A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2019
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib
Jan A Burger
Clinical Advances in Hematology & Oncology : H&O
|
May 12, 2016
Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia
Jan A Burger
American Journal of Obstetrics and Gynecology
|
April 9, 2008
A new model of ovarian carcinogenesis may influence early detection strategies
Robert A Burger
Expert Opinion on Medical Diagnostics
|
March 14, 2013
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
Jan A Burger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2007
Experience with bevacizumab in the management of epithelial ovarian cancer
Robert A Burger
Leukemia Research
|
December 19, 2008
CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you
Jan A Burger
Page
of 134
Search research articles
Search
Showing results (31-40 of 1,339) with videos related to
Sort By:
Page
of 134
The Journal of the Tennessee Dental Association
|
April 1, 1982
Touch your patient with love
P A Burger
Blood
|
January 9, 2016
Obinutuzumab: the more the merrier?
Jan A Burger
Blood
|
April 12, 2012
BRAF mutation: supporting diversity in HCL
Jan A Burger
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2011
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer
R A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2019
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib
Jan A Burger
Clinical Advances in Hematology & Oncology : H&O
|
May 12, 2016
Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia
Jan A Burger
American Journal of Obstetrics and Gynecology
|
April 9, 2008
A new model of ovarian carcinogenesis may influence early detection strategies
Robert A Burger
Expert Opinion on Medical Diagnostics
|
March 14, 2013
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
Jan A Burger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2007
Experience with bevacizumab in the management of epithelial ovarian cancer
Robert A Burger
Leukemia Research
|
December 19, 2008
CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you
Jan A Burger
Page
of 134